Ovid Therapeutics recently announced positive initial data from the ENDYMION trial, Phase 2 open-label extension study of soticlestat (OV935/TAK935) in patients with rare developmental and epileptic encephalopathies (DEE) such as Dravet syndrome and Lennox-Gastaut syndrome (LGS). Soticlestate is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24=hydroxylase (CH24H). It has the potential to reduce seizure susceptibility and improve seizure control.
The primary objective of the study is to assess the long-term safety and tolerability of soticlestat over 2 years of treatment and to evaluate the effect of soticlestat on seizure frequency over time. Seven adult patients with DEE who previously completed the 12-week Phase 1b/2a clinical trial were enrolled in the study. Findings suggest that prolonged treatment leads to a reduction in seizure frequency as well as a favorable safety and tolerability profile.
Read the press release here.